GENETIC ANALYSIS NK -60 (8V8) - Cash Flow Conversion Efficiency
Based on the latest financial reports, GENETIC ANALYSIS NK -60 (8V8) has a cash flow conversion efficiency ratio of -0.218x as of June 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (€-4.52 Million ≈ $-5.28 Million USD) by net assets (€20.71 Million ≈ $24.22 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see GENETIC ANALYSIS NK -60 market capitalisation for the company's overall valuation and market capitalisation.
GENETIC ANALYSIS NK -60 - Cash Flow Conversion Efficiency Trend (2021–2025)
This chart illustrates how GENETIC ANALYSIS NK -60's cash flow conversion efficiency has evolved over time, based on yearly financial data.
GENETIC ANALYSIS NK -60 Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of GENETIC ANALYSIS NK -60 ranked by their cash flow conversion efficiency. See GENETIC ANALYSIS NK -60 debt service capacity to evaluate how effectively operating cash flow covers total debt obligations.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Invion Ltd
AU:IVX
|
-0.163x |
|
ILYA Co. Ltd
KQ:058450
|
-0.054x |
|
Global Battery Metals Ltd
V:GBML
|
-0.020x |
|
CDN Maverick Capital Corp.
F:338B
|
-0.123x |
|
Photocat AS
ST:PCAT
|
-0.060x |
|
Inventronics Ltd
V:IVX
|
-0.005x |
|
Kestrel Gold Inc
V:KGC
|
-0.032x |
|
Laxmi Cotspin Limited
NSE:LAXMICOT
|
0.025x |
Annual Cash Flow Conversion Efficiency for GENETIC ANALYSIS NK -60 (2021–2025)
The table below shows the annual cash flow conversion efficiency of GENETIC ANALYSIS NK -60 from 2021 to 2025. View GENETIC ANALYSIS NK -60 stock quote for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | €27.08 Million ≈ $31.66 Million |
€2.40 Million ≈ $2.81 Million |
0.089x | +117.16% |
| 2024-12-31 | €22.49 Million ≈ $26.30 Million |
€-11.62 Million ≈ $-13.59 Million |
-0.517x | +4.04% |
| 2023-12-31 | €32.00 Million ≈ $37.41 Million |
€-17.23 Million ≈ $-20.15 Million |
-0.539x | -22.17% |
| 2022-12-31 | €44.14 Million ≈ $51.60 Million |
€-19.46 Million ≈ $-22.75 Million |
-0.441x | -15.07% |
| 2021-12-31 | €72.09 Million ≈ $84.28 Million |
€-27.62 Million ≈ $-32.29 Million |
-0.383x | -- |
About GENETIC ANALYSIS NK -60
Genetic Analysis AS, a science-based diagnostic company, engages in the research, development, manufacturing, and sale of diagnostic test solutions for human microbiome in the United States, Europe, and internationally. The company offers GA-map MHI Gut Health Test, a microbiome-based diagnostic test for antibiotic-induced microbiome imbalances; GA-map Dysbiosis Test, a diagnostic microbiome test… Read more